---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-002001"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:37:18.375866+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entera Bio raises $10M in private placement with BVF Partners to fund phase 3 osteoporosis study

## Summary
- Gross proceeds of ~$10.0M from sale of 7,827,789 units at $1.2775/unit to funds affiliated with BVF Partners LP.
- Each unit consists of one ordinary share (or pre-funded warrant) and one warrant to purchase 1.5 ordinary shares at $1.24/share.
- Warrants become exercisable 6 months after closing (April 2, 2026) and expire in 5 years; cash exercise could bring additional ~$14.5M.
- Net proceeds intended to support initiation of phase 3 registrational study of EB613 for postmenopausal osteoporosis and for working capital.

## SEC filing metadata
- accession: 0001178913-26-002001
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/0001178913-26-002001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/zk2634965.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-002001
- JSON: https://secwatch.observer/filing/0001178913-26-002001.json
- Plain text: https://secwatch.observer/filing/0001178913-26-002001.txt

## Key facts
- Equity Issuances
  Entera Bio Ltd. issued 7,827,789 units of unit to funds affiliated with BVF Partners LP for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).
  - Security: unit
  - Shares: 7,827,789 units
  - Purchaser: funds affiliated with BVF Partners LP
  - Consideration: aggregate proceeds of approximately $10.0 (or $1.2775 per Unit)
  source text: On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/0001178913-26-002001-index.htm
- Material Agreements
  Entera Bio Ltd. entered into Purchase Agreement with funds affiliated with BVF Partners LP valued at approximately $10.0 (effective 2026-04-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: funds affiliated with BVF Partners LP
  - Value: approximately $10.0
  - Effective: 2026-04-01
  source text: On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/0001178913-26-002001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.